Safety trial with the 5HT(1B/1D) agonist avitriptan (BMS-180048) in patients with migraine who have experienced pressure, tightness, and/or pain in the chest, neck, and/or throat following sumatriptan

Cephalalgia

Volumn 18, Issue 8, 1998, Pages 546-551

  Dahlof C G H ^a   Falk, L ^b   Risenfors, M ^b   Lewis, C P ^c  

^a Gothenburg Migraine Clinic   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Adverse events; Avitriptan; Chest symptoms; Migraine; Safety

Indexed keywords

AVITRIPTAN; SUMATRIPTAN; HTR1B PROTEIN, HUMAN; INDOLE DERIVATIVE; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN AGONIST; SEROTONIN RECEPTOR; SULFONAMIDE; TRYPTAMINE DERIVATIVE;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEART FUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MIGRAINE; NAUSEA; ORAL DRUG ADMINISTRATION; PARESTHESIA; THORAX PAIN; TREATMENT INDICATION; CHEMICALLY INDUCED DISORDER; DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; ECHOGRAPHY; ELECTROCARDIOGRAPHY; HEART MUSCLE ISCHEMIA; MIDDLE AGED; NECK PAIN; SAFETY;

ADULT; CHEST PAIN; DIAGNOSIS, DIFFERENTIAL; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; MIGRAINE DISORDERS; MYOCARDIAL ISCHEMIA; NECK PAIN; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; SAFETY; SEROTONIN AGONISTS; SULFONAMIDES; SUMATRIPTAN; TRYPTAMINES;

EID: 0031593368     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1998.1808546.x     Document Type: Article

References (57)

1. Hartig PR, Hoyer D, Humphrey PPA, Martin GR. Alignment of receptor nomenclature with the human genome: classification of 5HT1B and 5HT1D receptor subtypes. Trends Pharmacol Sci 1996;17:103-7
2. Hoyer D, Clarke DF. VIIth International Union of Pharmacology classification of receptors for 5-hydroxytryptamine. Pharmacol Rev 1994;46:157-204
3. Dechant KL, Clissold SP. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1992;43:776-98
4. Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994;47:622-51
5. Schoenen J. Acute migraine therapy: the newer drugs. Curr Opin Neurol 1997;10:237-43
6. Ferrari MD. Migraine. Lancet 1998;351:1043-51
7. Humphrey PP, Feniuk W. Mode of action of the antimigraine drug sumatriptan. Trends Pharmacol Sci 1991; 12:444-6
8. Rebeck GW, Maynard KI, Hyman BT, Moskowitz MA. Selective 5HT1D alpha serotonin receptor gene expression in trigeminal ganglia: implications for antimigraine drug development. Proc Natl Acad Sci USA 1994;91:3666-9
9. Goadsby PJ. Studies of cerebrovascular pain pathways of relevance to migraine. In: Olesen J, Moskowitz MA, editors. Experimental headache models. Philadelphia: Lippincott Raven Press, 1995
10. Goadsby PJ, Hoskin KL. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine? Pain 1996;67:355-9
11. Ottervanger JP, Wilson JH, Stricker BH. Drug-induced chest pain and myocardial infarction. Reports to a national centre and review of the literature. Eur J Clin Pharmacol 1997;53:105-10
12. Dahlöf C, Ekbom K, Persson L. Clinical experiences from Sweden on the use of subcutaneously administered sumatriptan in migraine and cluster headache. Arch Neurol 1994;51:1256-61
13. Dahlöf CG. How does sumatriptan perform in clinical practice? Cephalalgia 1995;15 Suppl 15:21-8
14. Lloyd K. The clinical profile of sumatriptan: safety and tolerability. Eur Neurol 1994;34 Suppl 2:40-3
15. Simmons VE, Blakeborough P. The safety profile of sumatriptan. Rev Contemp Pharmacother 1994;5:319-28
16. Visser WH, Jaspers NM, de Vriend RH, Ferrari MD. Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. Cephalalgia 1996;16:554-9
17. Bax WA, Renzenbrink GJ, Van Heuven-Nolsen D, Thijssen EJ, Bos E, Saxena PR. 5HT receptors mediating contractions of the isolated human coronary artery. Eur J Pharmacol 1993;239:203-10
18. Connor HE, Feniuk W, Humphrey PP. 5-hydroxytryptamine contracts human coronary arteries predominantly via 5HT2 receptor activation. Eur J Pharmacol 1989;161:91-4
19. Kaumann AJ, Frenken M, Posival H, Brown AM. Variable participation of 5HT1-like receptors and 5HT2 receptors in serotonin-induced contraction of human isolated coronary arteries. 5HT1-like receptors resemble cloned 5HT1D beta receptors. Circulation 1994;90:1141-53
20. Longmore J, Boulanger CM, Desta B, Hill RG, Schofield WN, Taylor AA. 5HT1D receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5HT and sumatriptan with rizatriptan and L-741,519. Br J Clin Pharmacol 1996;42:431-41
21. Longmore J, Hargreaves RJ, Boulanger CM, (all authors names please), et al. Comparison of the vasoconstrictor properties of the 5HT1D-receptor agonists rizatriptari (MK-462) and sumatriptan in human isolated coronary artery: outcome of two independent studies using different experimental protocols. Funct Neurol 1997;12:3-9
22. Macintyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS. The effect of i.v. sumatriptan, a selective 5HT1-receptor agonist on central haemodynamics and the coronary circulation. Br J Clin Pharmacol 1992;34:541-6
23. Saxena PR, Maassen VanDenBrink A, Heiligers JP, Scalbert E, Lemaitre BG. Effects of S20749, a close analogue of sumatriptan, on porcine carotid haemodynamics and human isolated coronary artery. Pharmacol Toxicol 1996;79:199-204
24. Saxena PR, De Vries P, Heiligers JP, (remaining authors please), et al. Investigations with GMC2021 in experimental models predictive of antimigraine activity and coronary side-effect potential. Eur J Pharmacol 1996;312:53-62
25. Saxena PR, De Vries P, Wang W, (remaining authors), et al. Effects of avitriptan, a new 5HT1B/1D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential. Naunyn Schmiedebergs Arch Pharmacol 1997;355:295-302
26. Maassen VanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998;98:25-30
27. Abbrescia VD, Pearlstein L, Kotler M. Sumatriptan-associated myocardial infarction: report of case with attention to potential risk factors. J Am Osteopath Assoc 1997;97:162-4
28. Abrahamsen B, Christiansen BD. [Angina pectoris after sumatriptan (Imigran)]. Ugeskr Laeger 1992;154:3602-3
29. Boyd IW, Rohan AP. Sumatriptan-induced chest pain [Letter; comment]. Lancet 1994;344:1704-5
30. Castle WM, Simmons VE. Coronary vasospasm and sumatriptan [Letter; comment]. BMJ 1992;305:117-8
31. de Jong EG. [Chest pain caused by sumatriptan (Letter; comment)]. Ned Tijdschr Geneeskd 1992;136:2142-3
32. Kelly KM. Cardiac arrest following use of sumatriptan. Neurology 1995;45:1211-3
33. Lippolis A, Castini D, Cirino D, Ornaghi M. [Coronary vasospasm secondary to subcutaneous administration of sumatriptan]. G Ital Cardiol 1994;24:883-6
34. McKirdy HC, Lowndes RH. Sumatriptan-induced chest pain [Letter; comment]. Lancet 1994;344:1501
35. Mueller L, Gallagher RM, Ciervo CA. Vasospasm-induced myocardial infarction with sumatriptan. Headache 1996;36: 329-31
36. O'Connor P, Gladstone P. Oral sumatriptan-associated transmural myocardial infarction. Neurology 1995;45: 2274-6
37. Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH. Transmural myocardial infarction with sumatriptan. Lancet 1993;341:861-2
38. Ottervanger JP, Valkenburg HA, Grobbee DE, Stricker BH. Characteristics and determinants of sumatriptan-associated chest pain. Arch Neurol 1997;54:1387-92
39. Peters RH, Meyburg HW, Westendorp PH, Westerhof PW. [Use of sumatriptan (Imigran) in a female patient with coronary spasm]. Ned Tijds Geneesk 1994;138:1872-4
40. Walton Shirley M, Flowers K, Whiteside JH. Unstable angina pectoris associated with Imitrex therapy [Letter]. Cathet Cardiovasc Diagn 1995;34:188
41. Willett F, Curzen N, Adams J, Armitage M. Coronary vasospasm induced by subcutaneous sumatriptan. BMJ 1992;304:1415
42. Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 1988;8 Suppl 7:1-96
43. Castro PF, Bourge RC, Foster RE. Evaluation of hibernating myocardium in patients with ischemic heart disease. Am J Med 1998;104:69-77
44. Song JK, Park SW, Kim JJ, (remaining authors please), et al. Values of intravenous ergonovine test with two-dimensional echocardiography for diagnosis of coronary artery spasm. J Am Soc Echocardiogr 1994;7:607-15
45. Lewis PJ, Barrington SF, Marsden PK, Maisey MN, Lewis LD. A study of the effects of sumatriptan on myocardial perfusion in healthy female migraineurs using 13NH3 positron emission tomography. Neurology 1997;48:1542-50
46. Dahlöf CGH, Mathew NT. Cardiovascular safety of 5HT1B/ 1D agonists - Any cause for concern? Cephalalgia 1998;18: 539-45
47. Dahlöf C. Sumatriptan injection and tablets in clinical practice: results of a survey of 707 migraineurs. Headache 1998
48. Hillis WS, Macintyre PD. Sumatriptan and chest pain [Letter; comment]. Lancet 1993;342:683
49. Lloyd DK, Simmons V. Adverse reactions associated with sumatriptan [Letter; comment]. Lancet 1993;341:1092
50. Stricker BH, Ottervanger JP. [Chest pain due to sumatriptan]. Ned Tijdschr Geneeskd 1992;136:1774-6
51. Hood S, Birnie D, MacIntyre PD, Hillis WS. Sumatriptan-induced chest pain [Letter; comment]. Lancet 1994;344:1500-1
52. Houghton LA, Foster JM, Whorwell PJ, Morris J, Fowler P. Is chest pain after sumatriptan oesophageal in origin? Lancet 1994;344:985-6
53. Nelson JA, Norris L, Welch KMA. Disturbance of muscle mitochondrial function is associated with side effects of sumatriptan. Cephalalgia 1997;17:427
54. Maassen VanDenBrink A, Bax WA, Ferrari MD, Zijlstra FJ, Bos E, Saxena PR. Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane. Br J Pharmacol 1996;119:855-62
55. MacLean MR, Clayton RA, Templeton AG, Morecroft I. Evidence for 5HT1-like receptor-mediated vasoconstriction in human pulmonary artery. Br J Pharmacol 1996;119:277-82
56. Loi V, Cherchi A, Pisano R, Del Zompo M. Can sumatriptan be anxiogenic in migraineurs? Cephalalgia 1996;16:36-7
57. Dahlöf C, Petersson A, Magnusson L, Pegenius G, Elam M. Is the sumatriptan-induced chest discomfort linked to a 5HT receptor dependent nociceptive sensitization? Cephalalgia 1998;17:430